Harmony Biosciences (NASDAQ:HRMY) Releases Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Harmony Biosciences (NASDAQ:HRMY) issued its earnings results on Thursday. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.21), FiscalAI reports. Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The company had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. During the same quarter in the previous year, the company posted $0.78 EPS. The company’s quarterly revenue was up 16.6% on a year-over-year basis.

Here are the key takeaways from Harmony Biosciences’ conference call:

• Harmony reported $215.4 million in Q1 net product revenue (up 17% YoY), about 8,500 average patients (8,600 exit), and reiterated full?year revenue guidance of $1.0B–$1.04B.
• The company is defending a multi?layered pitolisant IP estate after settling with 6 of 7 ANDA filers (LOE into March 2030) but faces ongoing ANDA litigation and a newly filed amorphous patent suit vs AET/Sandoz, creating legal uncertainty.
• BP?205 is presented as a potential best?in?class orexin?2 agonist with compelling preclinical data and is on track for phase I single ascending?dose PK topline data in mid?2026 and a U.S. IND submission later in 2026.
• Lifecycle programs are advancing — Pitolisant GR on track for NDA submission this quarter (PDUFA targeted Q1 2027), Pitolisant HD is enrolling two phase III trials (topline 2027), and Harmony has ~$878M cash to pursue BD opportunities targeting 2028–2032 revenues.

Harmony Biosciences Stock Performance

NASDAQ:HRMY traded down $1.36 during trading hours on Thursday, reaching $31.42. 2,229,892 shares of the company’s stock were exchanged, compared to its average volume of 868,104. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 11.59, a P/E/G ratio of 0.44 and a beta of 0.97. The company has a 50-day moving average of $29.01 and a 200 day moving average of $33.04. The company has a quick ratio of 3.58, a current ratio of 3.60 and a debt-to-equity ratio of 0.17. Harmony Biosciences has a 1-year low of $25.52 and a 1-year high of $40.87.

Institutional Trading of Harmony Biosciences

Large investors have recently bought and sold shares of the business. Amundi raised its position in Harmony Biosciences by 115.6% during the 1st quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after buying an additional 21,266 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Harmony Biosciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after buying an additional 984 shares during the last quarter. Empowered Funds LLC purchased a new position in Harmony Biosciences during the 1st quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after buying an additional 33,058 shares during the last quarter. Finally, Cetera Investment Advisers raised its position in Harmony Biosciences by 9.8% during the 2nd quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock worth $266,000 after buying an additional 748 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

HRMY has been the subject of several research analyst reports. UBS Group lowered their target price on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Truist Financial cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Weiss Ratings cut shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Bank of America decreased their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a research note on Wednesday, February 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Harmony Biosciences in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Harmony Biosciences currently has an average rating of “Hold” and a consensus target price of $42.67.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.